NIM
URGN icon

NEOS Investment Management’s UroGen Pharma URGN Stock Holding History

NEOS Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,576
Closed -$1.25M – 655
2025
Q4 		$1.25M Buy
53,576
+3,118
+6% +$67.6K 0.01% 524
2025
Q3 		$1.01M Buy
+50,458
New +$906K 0.01% 519

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

NEOS Investment Management's URGN Position: Q1 2026 in Review

NEOS Investment Management sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 53,576 shares — an estimated $1.25M sold.

NEOS Investment Management first reported a position in URGN in Q3 2025 and held it in 2 quarters. The position peaked at $1.25M in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • NEOS Investment Management reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 53,576 UroGen Pharma shares in Q1 2026, an estimated $1.25M.
  • NEOS Investment Management first reported a position in UroGen Pharma in Q3 2025 and held it in 2 quarters.
  • NEOS Investment Management's UroGen Pharma position peaked at $1.25M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.